Redwood City, CA, United States
Redwood City, CA, United States

Time filter

Source Type

Patent
OncoMed Pharmaceuticals | Date: 2017-01-11

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.


Patent
OncoMed Pharmaceuticals | Date: 2017-03-22

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2017-02-08

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly gastric cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit growth of a gastric tumor. Also described are methods of treating gastric cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a gastric tumor or gastric cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-07-14

The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.


Patent
OncoMed Pharmaceuticals | Date: 2016-04-01

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-05-05

Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.


Patent
OncoMed Pharmaceuticals | Date: 2016-05-27

Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-03-03

Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.


Patent
OncoMed Pharmaceuticals | Date: 2016-02-03

Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.


Patent
OncoMed Pharmaceuticals | Date: 2016-01-12

Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.

Loading OncoMed Pharmaceuticals collaborators
Loading OncoMed Pharmaceuticals collaborators